Aypar, E. Et Al. 2018. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.24, no.4 , 281-289.

Aypar, E., Izzettin, F. V., Aki, S. Z., SANCAR, M., YEGİN, Z. A., & Turkoz-Sucak, G., (2018). Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.24, no.4, 281-289.

Aypar, Eda Et Al. "Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.24, no.4, 281-289, 2018

Aypar, Eda Et Al. "Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.24, no.4, pp.281-289, 2018

Aypar, E. Et Al. (2018) . "Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.24, no.4, pp.281-289.

@article{article, author={Eda Aypar Et Al. }, title={Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2018, pages={281-289} }